ANI Pharmaceuticals, Inc. (ANIP) News
Track canonical SquawkNews coverage tagged to ANIP, ANI Pharmaceuticals, Inc.. This hub brings together deduplicated headlines about alpaca us equities, markets catalysts, earnings, analyst actions, and wider market events so traders can review how a developing story changed over time. It contains 11 indexed stories across 8 publication days and is ordered by the same first-publication timeline used by LiveCast.
L
ANI Pharmaceuticals Price Target Announced at $85.00/Share by Oppenheimer
Ratings actions from Benzinga: GMT) ANI Pharmaceuticals Initiated at Perform by OppenheimerRatings actions from Benzinga
NEWS | Sep 23, 2026, 12:14 PM UTC
L
ANI Pharmaceuticals, Inc. (ANIP) Wins FDA OK for Everolimus Oral Suspension Generic
ANI Pharmaceuticals received FDA final approval for its ANDA for Everolimus Tablets for Oral Suspension (2mg, 3mg, 5mg), the generic of Afinitor Disperz. U.S. annual sales for the reference market are approximately $123M
REGULATION | Sep 23, 2026, 11:02 AM UTC
L
ANIP - ANI Pharmaceuticals Announces the FDA Approval of Everolimus Tablets for Oral Suspension
ANIP - ANI Pharmaceuticals Announces the FDA Approval of Everolimus Tablets for Oral Suspension
REGULATION | Sep 23, 2026, 10:55 AM UTC
H
ANIP: Rare disease focus, sales force expansion, and clinical data drive strong growth outlook
The company is rapidly expanding its rare disease portfolio, with Cortrophin Gel and ILUVIEN driving growth and a strong generics business funding further investment. Revised 2026 guidance reflects Q1 headwinds, but robu
EARNINGS | Sep 15, 2026, 04:44 PM UTC
L
ANI Pharmaceuticals CEO to take part in September investor fireside chats
ANI Pharmaceuticals said CEO Nikhil Lalwani and members of its executive leadership team will participate in fireside chats at September investor conferences.
EQUITY | Sep 03, 2026, 10:57 AM UTC
L
ANIP - ANI Pharmaceuticals to Present at September Investor Conferences
ANIP - ANI Pharmaceuticals to Present at September Investor Conferences
EQUITY | Sep 03, 2026, 10:55 AM UTC
L
ANI Pharmaceuticals appoints Henry Gosebruch to board
ANI Pharmaceuticals says it has appointed Henry Gosebruch to its board of directors.
REGULATION | Aug 24, 2026, 10:55 AM UTC
L
These Analysts Slash Their Forecasts On ANI Pharmaceuticals After Q2 Results
ANI Pharmaceuticals Inc (NASDAQ: ANIP ) reported upbeat earnings for the second quarter on Friday. The company posted quarterly earnings of $2.21 per share which beat the analyst consensus estimate of $2.05 per share. Th
EARNINGS | Aug 10, 2026, 02:39 PM UTC
L
ANI Pharmaceuticals Affirms FY2026 Adj EPS Guidance of $9.19-$9.69 vs $9.45 Est; Affirms FY2026 Sales Guidance of $1.080B-$1.140B vs $1.119B
ANI Pharmaceuticals (NASDAQ: ANIP ) affirms FY2026 Adj EPS guidance from $9.19-$9.69 to $9.19-$9.69 vs $9.45 analyst estimate. Affirms FY2026 sales outlook from $1.080 billion-$1.140 billion to $1.080 billion-$1.140 bill
EARNINGS | Aug 07, 2026, 10:53 AM UTC
L
ANIP Initiated Hold and $91 PT @ Canaccord
ANIP Initiated Hold and $91 PT @ Canaccord
EQUITY | Jul 17, 2026, 12:29 PM UTC
L
ANIP Ani Pharmaceuticals announces intent to appeal rulings in Cg Oncology matter Ani Pharmaceuticals - trial court denies Ani Pharmaceutica
ANIP Ani Pharmaceuticals announces intent to appeal rulings in Cg Oncology matter Ani Pharmaceuticals - trial court denies Ani Pharmaceuticals' Motion for new trial and judgment Ani Pharmaceuticals Inc: continue to seek
EQUITY | Jul 16, 2026, 08:35 PM UTC